“We were able to show multiple datasets that actually deliver against this vision that antibody drug conjugates can improve on and therefore displace chemotherapy” says Dr. Susan Galbraith, AstraZeneca’s EVP of oncology R&D. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli to break down key findings from ESMO — from early-line HER2 breast cancer data to progress in bladder and lung cancer. She details the promise of Enhertu and Datopotamab, AstraZeneca’s antibody-drug conjugates (ADCs), and how their work may transform cancer treatment in curative settings.

<p>&ldquo;We were able to show multiple datasets that actually deliver against this vision that antibody drug conjugates can improve on and therefore displace chemotherapy&rdquo; says Dr. Susan Galbraith, AstraZeneca&rsquo;s EVP of oncology R&amp;D. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli to break down key findings from ESMO &mdash; from early-line HER2 breast cancer data to progress in bladder and lung cancer. She details the promise of Enhertu and Datopotamab, AstraZeneca&rsquo;s antibody-drug conjugates (ADCs), and how their work may transform cancer treatment in curative settings.</p>

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

<p>Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.</p>

Vanguards of Healthcare by Bloomberg Intelligence

Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/59588c92-6e41-400d-818e-b38300c4cbed/transcript